Jumpcan Pharmaceutical released its 2026 interim report. During the reporting period, the company's total operating revenue was 2.328 billion yuan, down 15.29 percent year on year, and net profit attributable to the parent company was 784 million yuan. Net cash inflow from operating activities was 855 million yuan, down 12.13 percent year on year. The company's asset-liability ratio was 18.78 percent, gross margin was 79.48 percent, and diluted earnings per share was 0.85 yuan. The number of shareholders was 32,700, and the top ten shareholders held 71.63 percent of total share capital.
Hubei Jumpcan Pharmaceutical Co LtdRevenue down 15.29% YoY, though net profit 784M yuan; report shows financial results.
